PPB Pharmacist Exam common mistakes
PPB Pharmacist Exam · Understand the traps and how to avoid them.
Confusing the roles of the marketing authorisation holder (MAH) and the manufacturer when answering questions about variation applications, batch release, and pharmacovigilance responsibilities.
Candidates study the definitions in isolation but do not map them to real scenarios; they assume the manufacturer is always the MAH or that the MAH is always the licence holder in the country.
What to do instead
For each domain, create a two-column table: MAH obligations vs. manufacturer obligations. Practice with past-style scenarios where the MAH outsources manufacturing or where the manufacturer is in a third country. Emphasise that the MAH is the legal entity responsible for the product on the market, regardless of who makes it.
Mixing up the types of licences (e.g., wholesale dealer's licence, manufacturing licence, import licence) and which activities each permits, especially for parallel imports and brokering.
The licence names sound similar and candidates memorise lists without linking each licence to specific activities and responsible persons.
What to do instead
Build a matrix of licence types vs. permitted activities (storage, distribution, import, export, brokering). For each, note who must be named (e.g., responsible person) and key conditions. Test yourself by classifying 20 activity descriptions into the correct licence category.
Applying hospital or community pharmacy standard operating procedures to regulatory inspection scenarios without distinguishing between good pharmacy practice (GPP) and good manufacturing practice (GMP) or good distribution practice (GDP).
Candidates with pharmacy practice background over-rely on GPP and fail to recognise that inspections of wholesale or manufacturing sites follow different standards.
What to do instead
Review the scope of GPP, GDP, and GMP. For each, list the key principles (e.g., premises, documentation, personnel, complaints, recalls). Then answer inspection questions by first identifying the activity (dispensing, wholesale, manufacturing) and then applying the correct standard.
Treating continuing professional development (CPD) as a passive record-keeping exercise and failing to describe the cycle (reflect, plan, act, evaluate) or how it is evidenced for revalidation.
Candidates skim CPD requirements and assume it is just about collecting points or hours, missing the reflective and outcomes-based nature.
What to do instead
Write a one-page summary of the CPD cycle with examples of evidence for each stage. Practice questions that ask what constitutes a valid CPD entry or how to demonstrate impact on practice. Link CPD to professional standards and revalidation requirements.
Underestimating the importance of inspection classification (critical, major, other) and the follow-up actions (e.g., statement of non-compliance, re-inspection) when answering regulatory inspection questions.
Candidates focus on the inspection process but not on the consequences of findings, leading to vague answers about what happens after an inspection.
What to do instead
Learn the definitions of critical, major, and other deficiencies with examples. Map each classification to potential regulatory action (e.g., suspension of licence, referral to compliance management). Use case studies to practice classifying findings and predicting outcomes.
Confusing the roles of the sponsor, investigator, and ethics committee in clinical trial authorisation and oversight, especially regarding who submits applications and who reports safety issues.
The terms are defined in guidelines but candidates do not internalise the division of responsibilities across the trial lifecycle.
What to do instead
Create a responsibility chart for each phase (application, conduct, safety reporting, close-out). Highlight that the sponsor initiates and manages the trial, the investigator conducts it, and the ethics committee provides ethical approval. Practice with scenario questions where one party's action is described and you must identify the correct party.
Assuming that market surveillance is only about testing product quality and ignoring the broader components such as labelling review, advertising monitoring, and internet sales enforcement.
Candidates associate surveillance with laboratory testing and miss the regulatory and administrative aspects.
What to do instead
List all surveillance activities: sampling and testing, label and package insert review, monitoring of advertising and promotion, inspection of distribution channels, and control of online sales. For each, note the legal basis and responsible authority. Practice questions that describe a surveillance action and ask which component it belongs to.
Mixing up the reporting timelines and responsibilities for adverse drug reactions (ADRs) between marketing authorisation holders and national competent authorities, and between serious and non-serious cases.
Candidates memorise numbers without linking them to the reporter and case seriousness, leading to errors in scenario-based questions.
What to do instead
Create a timeline table: for each report type (e.g., serious unexpected suspected adverse reaction, periodic safety update report), list who reports, to whom, and the timeframe. Use mnemonics for key intervals (e.g., 15 days for serious unexpected). Practice with dates to calculate deadlines.
Confusing quality control testing (e.g., in-process controls, finished product testing) with lot release procedures (e.g., official control authority batch release, summary lot protocol) and the role of the qualified person.
Candidates treat all laboratory activities as the same and do not distinguish between routine QC, batch release by the manufacturer, and independent lot release for certain products (e.g., vaccines).
What to do instead
Define QC, lot release, and QP certification. Explain when official lot release is required and what documents are involved (e.g., summary lot protocol). Compare manufacturer's release vs. official release. Practice questions that describe a testing scenario and ask which process it is.
Treating online systems (e.g., e-submission portals, pharmacovigilance databases, licensing databases) as isolated tools and failing to understand how data flows between them and the regulatory implications of electronic submissions.
Candidates learn the purpose of each system but not the interoperability, data standards (e.g., HL7, ISO IDMP), or legal validity of electronic signatures and records.
What to do instead
Map the regulatory processes to the systems that support them (e.g., application submission, safety reporting, inspection tracking). Learn key data standards and the requirements for electronic records and signatures. Practice questions that describe a process and ask which system is used or what data standard applies.